Most Recent
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.
Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.
Andrew ‘Twiggy’ Forrest’s Fortescue can't get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.
Samsung Bioepis has successfully opposed Janssen's bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
‘Argumentative and amorphous’: Startup attacks Fortescue’s call for seized docs in trade secrets row
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
The High Court has rejected Novartis' plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.